1st
The Alliance for mRNA Medicines (AMM) brings together senior executives and top decision-makers in the mRNA industry to advance pioneering research into vaccines and therapies for patients. The annual meeting features one-on-one partnering opportunities for companies and investors, dedicated networking, keynotes and fireside chats featuring KOLs and industry visionaries, as well as engaging plenary and panel discussions among biotech, pharma, and academic leaders.
The Alliance for mRNA Medicines (AMM) brings together senior executives and top decision-makers in the mRNA industry to advance pioneering research into vaccines and therapies for patients. The annual meeting features one-on-one partnering opportunities for companies and investors, dedicated networking, keynotes and fireside chats featuring KOLs and industry visionaries, as well as engaging plenary and panel discussions among biotech, pharma, and academic leaders.
November 13–15, 2024
Hilton Boston Park Plaza Hotel
50 Park Plaza, Boston, MA 02116, USA
Through the power of the partneringONE partnering platform, attendees can search, connect, and schedule 1:1 meetings with potential partners to identify opportunities, build relationships, and move deals forward.
Ample dedicated networking opportunies to connect with other industry leaders and potential partners.
Learn from senior executives and top decision-makers in the mRNA industry to advance pioneering research into vaccines and therapies for patients with engaging speakers, fireside chats, and panel discussions.
Our sessions will feature some of the leading voices in the mRNA industry, sharing their unique insights and expertise. Currently confirmed speakers include:
Director, Center for Biologics Evaluation and Research, FDA
Deputy Center Director, Center for Biologics Evaluation and Research, FDA
Chief Development Officer and Co-Founder, Replicate Bioscience
Director of Process Development, Curia
Vice President, Process Development & RNA Technology, Verve Therapeutics
Bloomberg Distinguished Professor of RNA Biology and Therapeutics, Johns Hopkins University
President, Society for RNA Therapeutics; Professor & Chair, Dept. of Cardiovascular Sciences, Houston Methodist Hospital and Academic Institute
Managing Director, Matrix Capital Management Company, L.P.
Chief Technology Officer & Global Head of Research, mRNA Center of Excellence, Sanofi
Chief Strategy Officer, Arcturus
CEO and Co-Founder, Sensible Biotechnologies
Portfolio Manager, Regulated Markets, New England Biolabs
Senior Vice President, Corporate Affairs, ReCode
Strategic Customer Leader – NanoMedicines, Cytiva
Senior Vice President, Business and Corporate Development, ReCode
CSO/CTO, Danaher Genomic Medicines
SVP of RNA Biochemistry and Manufacturing, BioNTech
Chief Strategy Officer and Co-Founder, Nanovation Therapeutics
President, Project Farma and Precision ADVANCE
Biotech Sector Lead, Private Equity, Wellington
President and CEO, MaxCyte
Founder and CEO, Cytonus
CEO, Sail Biomedicines
Managing Director, Capitol Street
Senior Director of Innovation & Strategy, Aldevron
Site Leader, mRNA, Thermo Fischer Scientific
Chief Scientific Officer, Acuitas
Senior Research Analyst, Piper Sandler
Head of Nucleic Acid Development, ReciBioPharm
The meeting is scheduled to begin after the mRNA Health conference has concluded.
Registration Desk, 1:1 Partnering, and Sponsor Exhibits Open
Happy Hour
Registration Desk, 1:1 Partnering, and Sponsor Exhibits Open
Welcome
State of the Industry
Panel of speakers presenting the latest in scientific developments, where the field is going next, and major issues on the horizon crossing standards, regulatory, and business.
Break
Regulatory Outlook
High level FDA officials provide the Agency’s perspective on the regulatory outlook for mRNA medicines, key issues they are grappling with, and the latest on platform technology guidance.
Networking Reception
Breakfast Buffet
Registration Desk, 1:1 Partnering, and Sponsor Exhibits Open
Day 2 Welcome
Scientific Update
Panel discussion on hot topics in mRNA such as gene editing and protein replacement.
Manufacturing, CMC, and Analytics
Panel discussion considering how the mRNA sector is overcoming manufacturing bottlenecks experienced by the cell and gene therapy industry.
Break
mRNA Delivery
Panel discussion on the pressing issues in mRNA delivery, including novel delivery technologies and optimizing mRNA delivery for different applications.
Lunch Buffet
2024 Election: What Does It Mean for the mRNA Sector?
Presentation and outlook discussion about what the election outcomes mean for mRNA medicines.
Investor Perspectives
Presentation of data about the industry and panel discussion with leading institutional investors sharing their perspective on what is driving their interest in mRNA technologies.
Closing Panel: Our mRNA Future
Final panel shares thoughts about the future of mRNA development and what we expect over the next decade.
Partnering is different from networking! It’s planning to meet because you have something to discuss rather than finding something to discuss because you happen to meet. Successful partnering is tied to pre-event preparation. With the support of EBD Group’s partneringONE™, arranging one-to-one meetings with your target companies is a breeze.
AMM is grateful to the partners whose support is making AMM ASCENT possible. Interested in becoming a sponsor? Contact [email protected] to learn more.
GOLD SPONSOR
SILVER SPONSORS
BRONZE SPONSORS
The Alliance for mRNA Medicines (AMM) is the leading global organization dedicated to advancing and advocating for mRNA and next-generation encoding RNA therapeutics and vaccines for the benefit of patients, public health, and society. Our mission is to propel the future of mRNA medicine, improve patients’ lives, and advance scientific knowledge by convening and empowering mRNA industry leaders, innovators, scientists, and other key stakeholders.